Skip to main content
S&P 5007,794.26-0.32%DOW51,182.13-0.66%NASDAQ27,470.58-0.47%BTC$83,404.00-2.68%ETH$2,565.50-4.97%GOLD$4,136.50-1.21%OIL$88.91-0.59%
Smart Investors Daily
SID Premium
AB

NASDAQ · ABVX

Abivax S.A.

Healthcare · Biotechnology

$88.22

Down-$0.71 (-0.80%)

Updated Oct 7, 2026, 4:48 PM

SID Score

4.0/10

Composite research score

Smart Money

56/100

Neutral

Market cap
7.95B
P/E ratio
-33.3
Dividend yield
0.00%
52-week range
$69.81 – $148.83
Volume
2M
Avg. volume
1.52M

Price performance · ABVX

ABVX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

ABVX closed at $88.22 after 21 trading sessions, down 25.83% for the selected period.

Last close
$88.22
Period change
-25.83%
Period low
$88.22
Period high
$119.46
Daily close
View OHLC price history
ABVX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$93.67$93.67$87.83$88.222M
Oct 5, 2026$92.27$92.61$89.40$91.73840.31K
Oct 2, 2026$95.82$95.82$92.58$92.88644.38K
Oct 1, 2026$96.60$97.125$93.87$95.101.24M
Sep 30, 2026$99.335$100.08$97.46$99.02886.23K
Sep 29, 2026$96.97$99.17$94.40$98.501.63M
Sep 28, 2026$91.50$97.27$91.45$96.851.68M
Sep 25, 2026$94.00$94.16$90.96$91.061.48M
Sep 24, 2026$92.97$95.88$91.96$94.871.66M
Sep 23, 2026$98.30$98.50$92.57$94.132.64M
Sep 22, 2026$102.74$102.74$96.74$98.292.53M
Sep 21, 2026$105.72$105.72$102.52$103.45974.84K
Sep 18, 2026$107.00$107.185$103.89$105.04876.03K
Sep 17, 2026$104.59$107.60$104.15$106.991.15M
Sep 16, 2026$106.38$107.1599$101.2873$102.231.89M
Sep 15, 2026$113.00$113.105$106.0004$106.662.01M
Sep 14, 2026$116.66$117.135$113.20$113.581.16M
Sep 11, 2026$115.46$119.0199$114.68$118.64893.45K
Sep 10, 2026$117.80$118.75$114.3019$115.951.29M
Sep 9, 2026$118.19$120.63$116.625$119.46987.18K
Sep 8, 2026$114.00$120.30$112.95$118.951.61M

Latest ABVX news

The latest Smart Investors Daily articles mentioning ABVX.

Stock researchCompany · Overview

ABVX research

Overview

Company profile and research snapshot.

Company profile

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$130.86
Implied upside
—
Analysts
—
ABVX recent ratings
DateFirmRatingTarget
Sep 22, 2026STIFEL EUROPEBuy—
Sep 22, 2026BTIGBuy—
Sep 22, 2026ODDO BHFBuy—
Jul 6, 2026ODDO BHFBuy—
Jul 5, 2026ODDO BHFBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 30, 2026

Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026

Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026 Four oral presentations and three posters build upon Phase 3 ABTECT Maintenance and Induction programs in ulcerative colitis, long-term Phase 2 findings, and preclinical anti-fibrotic research PARIS, France – September 30, 2026 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics

Yahoo · Sep 27, 2026

ABIVAX Société Anonyme (ENXTPA:ABVX) Just Gave Investors Something To Think About

ABIVAX Société Anonyme (ENXTPA:ABVX) has just paired deeper operating cash use and wider losses with fresh leadership hires and extended funding, creating a complex backdrop for anyone tracking the stock today. Recent moves have come against a tougher tape for ABIVAX Société Anonyme, with the share price down 28.78% year to date and 15.91% over 30 days, even as the 1 year total shareholder return of 16.50% and the very large 3 year total shareholder return of 446.00% point to longer term...

Yahoo · Sep 26, 2026

ABIVAX Société Anonyme (ENXTPA:ABVX) Appoints New Chief Medical And Technical Officers

ABIVAX Société Anonyme (ENXTPA:ABVX) has appointed a new Chief Medical Officer and a new Chief Technical Officer. The fresh leadership roles are focused on medical strategy, product development and technical operations across Abivax SA's pipeline. The appointments are intended to support the firm's efforts around clinical programs and preparation for potential commercialization activities. The appointment of a new Chief Medical Officer and Chief Technical Officer should not be the only...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By